findmyKOL
Clinical trialNCT03420014UnknownPhase 2Interventional

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

SponsorPhilogen S.p.A.Enrollment114Leiomyosarcoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Hospital

    Phoenix, Arizona, United States

    Recruiting
  • Sarcoma Oncology Research Center (sorc) Cancer Center of Southern California

    Santa Monica, California, United States

    Recruiting
  • Mayo Clinic Hospital

    Jacksonville, Florida, United States

    Recruiting
  • Mayo Clinic

    Rochester, Minnesota, United States

    Recruiting
  • Washington University

    St Louis, Missouri, United States

    Recruiting
  • Rutgers Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, Nj 08901 Room 2031

    New Brunswick, New Jersey, United States

    Recruiting
  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

    Recruiting
  • Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, Wa 98109 Mail Stop Ce2-128

    Seattle, Washington, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Doxorubicin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Dec 2018
Primary completion
31 Dec 2024
Completion
31 Dec 2025
Last update posted
10 Oct 2023
Registered enrollment
114
Registry id
NCT03420014
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.